FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
The key to fibrinolysis and thrombolysis
1705PDF: 531HTML: 264 -
Diagnostic and management practices for inherited fibrinogen disorders: a nationwide survey of Italian Hemophilia Treatment Centers
933PDF: 121HTML: 130Supplementary: 79Appendix: 80 -
Anticoagulation in obese patients: challenges and strategies
2042PDF: 542HTML: 308XML: 193 -
PO150 | FACTOR XII DEFICIENCY IN THE SETTING OF RECURRENT THROMBOSIS AND EXTENDED VENOUS OBSTRUCTION: A CASE ANALYSIS L. Leoni1, G. Pata1, A. Domenighini1, L. Crippa2, T. D'aliberti1, G. Galimberti1, F. Paciullo1, P. Rovere Querini1 | 1Internal Medicine Unit; 2Coagulation Service Thrombosis Research Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy
35PDF: 15 -
PO22 | Early detection and management of PICC-related thrombosis in oncohematologic patients through serial ultrasound monitoring: a prospective observational study S. Laurenti, M. Schneeberger, G. Rosati, A. Pozzi, M. Padrini, R. Vacchelli, A. Morotti | University of Turin, AUO San Luigi Gonzaga, Orbassano (TO), Italy
658PDF: 32 -
OC04 | DIRECT ORAL ANTICOAGULANTS PROVIDE EFFECTIVE THROMBOPROPHYLAXIS IN NEWLY DIAGNOSED MYELOMA: REAL WORLD FINDINGS FROM THE ATOMM STUDY T. Bull1, Heamstar Collaborators2, W. Wilson3, E. Ganendra4, M. Thomas5, R. Alikhan6, M. Karanth1, M. Camilleri7 | 1West Suffolk Hospital NHS Foundation Trust, UK; 2Haematology Specialty Training Audit and Research HaemSTAR Network, UK; 3University College London Clinical Trial Centre, UK; 4North West Anglia NHS Foundation Trust, UK; 5University College London Hospitals, UK; 6Cardiff and Vale University Health Board, Wales, UK; 7Cambridge University Hospitals NHS Foundation Trust, UK
635PDF: 137 -
The landscape of rare coagulation factor deficiency management in Italy: a national hemophilia center survey
1366PDF: 221HTML: 137Appendix: 121 -
Thrombin generation assay in COVID-19 patients shows a hypocoagulable pattern
2513PDF: 510Supplementary: 264 -
PO011 | A TWO CENTERS REAL-WORLD EXPERIENCE WITH ANTI-XA DIRECT ORAL ANTICOAGULANTS IN CANCER PATIENTS WITH UNUSUAL SITE VEIN THROMBOSIS U. Mazzarelli1, L. Agrelli1, A. Cirillo1, C. Caputo2, M. Romano2, R. Russo2, R. Guarrasi3, M. Triggiani1, A. Tufano2, A. Guida4 | 1Dipartimento di Medicina Interna, Università degli studi di Salerno, Italy; 2Dipartimento di Medicina Interna, Università degli studi di Napoli Federico II, Italy; 3UOC Clinica Oncologica; 4Centro per le malattie emorragiche congenite e malattie trombotiche AOU San Giovanni di Dio e Ruggi d'Aragona Salerno, Italy
57PDF: 19 -
OC02 | INCIDENCE AND PREDICTORS OF ARTERIAL THROMBOSIS IN CANCER PATIENTS: RESULTS FROM THE PROSPECTIVE COMPASS-ARTERIAL CANCER ASSOCIATED THROMBOSIS (COMPASS-ARTECAT) STUDY M. Drakopoulou1, I. Diamandoulaki2, P. Baglaridis1, P. Las Casa3, P. Van Dreden4, K. Toutouzas1, G. Gerotziafas4|5 | 1First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, Athens, Greece; 2Department of Electrical and Computer Engineering, Aristotle University of Thessaloniki, Thessaloniki, Greece; 3Sorbonne University, INSERM UMR_S_938, CRSA, Research Department "Cancer, Vessels, Biology and Therapeutics" (CaVITE), Research Group "Cancer-Angiogenesis-Thrombosis and Haemostasis," Thrombosis Center, University Institute of Cancerology (UIC), Saint Antoine University Hospital Assistance Publique Hôpitaux de Paris (AP-HP) Paris France; 4Diagnostica Stago, clinical research, Gennevilliers, France; 5Center of Translational Research and Education, Department of Pathology and Laboratory Medicine, Loyola University Stritch School of Medicine, Maywood, Ill., USA
522PDF: 133 -
PO54 | CANCER-ASSOCIATED THROMBOSIS IN ASPIRIN-TREATED PATIENTS AFTER ARTERIAL THROMBOSIS: THE COMPASS-ARTECAT-ASA PROSPECTIVE COHORT STUDY G. Gerotziafas1|3|4|5, S. Allakhverdieva6, P. Henrique Fernandes Do Carmo Las Casa1, P. Van Dreden1|2, J. Fareed3, N. Lomakin6 , I. Zotova6, L. Buryachkovskaya7 | 1Sorbonne University, INSERM UMR_S_938, CRSA, Research Department "Cancer, Vessels, Biology and Therapeutics" (CaVITE), Research Group "Cancer-Angiogenesis-Thrombosis and Haemostasis," Thrombosis Center, University Institute of Cancerology (UIC), Saint Antoine University Hospital Assistance Publique Hôpitaux de Paris (AP-HP), Paris, France; 2Clinical Research, Diagnostica Stago, Gennevilliers, France; 3Center of Translational Research and Education, Department of Pathology and Laboratory Medicine, Loyola University Stritch School of Medicine, Maywood, Chicago, USA; 4Thrombosis Center, Department of Obstetrics, Gynecology and Perinatal Medicine, The I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; 5VAS-European Independent Foundation in Angiology/Vascular Medicine Milan, Italy; 6Federal State Budgetary Educational Institution of Further Professional Education "Russian Medical Academy of Continuous Professional Education" of the Ministry of Healthcare of the Russian Federation, Moscow, Russia; 7Federal State Budgetary Institution «National Medical Research Centre of Cardiology Named After Academician E. I. Chazov» of the Ministry of Health of the Russian Federation, Moscow, Russia
470PDF: 106 -
PO25 | EVOLUTION OF ANTICOAGULANT STRATEGIES AND CLINICAL OUTCOMES IN CANCER-ASSOCIATED THROMBOSIS: A LONGITUDINAL ANALYSIS OF THE START2 REGISTRY ONCO-VTE M. Marchetti1|2, T. Zollner1|2, OC. Cretu1|2, A. Chistolini3, R. Pancani4, L. Puccetti5, P. Sivera6, W. Ageno7, G. Elmi8, V. Fregoni9, V. Tonelli10, E. Antonucci11, D. Poli11|12, A. Falanga1|2, L. Barcella1|2 | 1Hemostasis & Thrombosis Center, Department of Transfusion Medicine, Papa Giovanni XXIII Hospital, Bergamo Italy; 2ERN EuroBloodNet; 3Hematology Unit, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy; 4Pulmonary Unit, Hospital of Siena, University of Siena, Siena, Italy; 5Hemostasis and Thrombosis Unit, Hospital of Siena, University of Siena, Siena, Italy; 6Haematology Unit, Ordine Mauriziano Hospital, Turin, Italy; 7Department of Medicine, University of Padua, Padua, Italy; 8Department of Medicine, Maggiore Hospital, Bologna, Italy; 9Department of Medicine, Sondalo Hospital, Sondalo, Italy; 10Angiology Unit, Sant'Eugenio Hospital, Rome, Italy; 11Arianna Anticoagulazione Foundation, Bologna, Italy; 12Department of Critical Care Medicine, Thrombosis Centre, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy
445PDF: 92 -
PO38 | PERICATHETER AND SYSTEMIC THROMBOSIS DURING CAR-T LYMPHOCYTAPHERESIS: INCIDENCE AND CLINICAL CORRELATES I. Pansini1|2, E. Galli1, A. Corrente2, N. Piccirillo1|2, M. Viscovo1|2, S. Hohaus1|2, P. Chiusolo1|2, F. Sorà1|2, S. Sica1|2 | 1Department of Laboratory and Hematologic Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome; 2Hematology Section, Department of Radiologic and Hematologic Sciences, Università Cattolica del Sacro Cuore, Rome, Italy
448PDF: 102 -
PO58 | TACKLING THE AWARENESS GAP IN CANCER-ASSOCIATED THROMBOSIS: IMPACT OF A BRIEF EDUCATIONAL INTERVENTION IN PATIENTS WITH GYNECOLOGICAL CANCERS P. Santini, F. Mancinetti, G. Fracassa, E. Fondi, E. Ianuà, A. D'Errico, M. Bigossi, C. Marchetti, V. Salutari, G. Scambia, C. Nero, R. Pola | Agostino Gemelli University Hospital Foundation IRCCS, Rome, Italy
521PDF: 106 -
CO-73 | WHEN BLEEDING MIMICS THROMBOSIS: DIAGNOSTIC DELAY AND THROMBOTIC COMPLICATIONS IN ACQUIRED HEMOPHILIA A R. Tomasello1, M. Mattana1, S. Raso1, F. Schirò1, P. Polidori2, M.I. Di Lena3, F. La Gattuta4, M. Napolitano1 | 1Ematologia e malattie rare, PO Cervello di Palermo, Italy; 2Farmacia ospedaliera, PO Cervello di Palermo, Italy; 3Direzione medica, PO Cervello di Palermo, Italy; 4Radiologia interventistica, PO Villa Sofia di Palermo, Italy
66PDF: 14 -
PO79 | Trying to hit the hit in the shadow of renal failure: a complex case managed with danaparoid S. Chessa1,2, M. Anedda2, M.V. Cherchi2, M. Vacca1,2, M. Caboni2, J. Pilia2, A.M. Bussu2, M. Mantega2, G. Costanzo1, D. Firinu1, S. Del Giacco1, A. Mameli3, D. Barcellona3 | 1Department of Medical Science and Public Health, University of Cagliari; 2Internal Medicine, ASL Sulcis, PO Sirai, Carbonia; 3Department of Medical Sciences and Public Health, Hemostasis and Thrombosis Unit, University of Cagliari and AOU of Cagliari, Italy
671PDF: 15 -
PO59 | Efficacy and safety of different anticoagulant treatment regimens for isolated internal jugular vein thrombosis: a case series A. Pannunzio1, E. Valeriani1, I.M. Palumbo1, S. Marucci2, D. Menichelli1, D. Pastori2, P. Pignatelli2 | 1Department of General Surgery and Surgical Specialty, Sapienza University of Roma; 2Department of Clinical, Internal Medicine, Anaesthesiological and Cardiovascular Sciences, Sapienza University of Roma, Italy
704PDF: 37 -
When a feminist platelet went to the convention of prostaglandins and thromboxanes
1271PDF: 164HTML: 189Italian version: 105 -
CO12 | Left internal carotid artery thrombosis in a patient with antiphospholipid antibody syndrome successfully treated with eculizumab A. Hoxha1, L. Nico2, F. Viaro3, L. Fabris1, Y.F. Herrera1, M. Munari4, C. Baracchini3, F. Causin2, P. Simioni1 | 1Internal Medicine Unit, Thrombotic and Haemorrhagic Centre, Department of Medicine - DIMED, University of Padua; 2Neuradiology Unit, University Hospital of Padua; 3Stroke Unit, Neurology Department, University of Padua; 4Intensive Care Unit, University Hospital of Padua, Italy
688PDF: 25 -
PO121 | IMMUNOTHROMBOSIS AND MULTIPLE-SITE VENOUS THROMBOEMBOLISM IN ACUTE TOXOPLASMOSIS: A CASE REPORT A. Grembiale1, A. Sabena1, G. Dettori1, C. Grendene1, S. Grazioli1, S. Venturini2 | 1SOC Medicina Interna 2 - Azienda Sanitaria Friuli Occidentale - Pordenone, Italy; 2SSD Malattie Infettive - Azienda Sanitaria Friuli Occidentale - Pordenone, Italy
31PDF: 15 -
CO015 | EVOLUTION OF ANTICOAGULANT THERAPY FOR CANCER-ASSOCIATED THROMBOSIS: THE START2 REGISTRY ONCO-VTE LONGITUDINAL STUDY M. Marchetti1|2, T. Zollner1|2, O.C. Cretu1|2, A. Chistolini3, R. Pancani4, L. Puccetti5, P. Sivera6, W. Ageno7, G. Elmi8, V. Fregoni9, V. Tonelli10, E. Antonucci11, D. Poli11|12, A. Falanga1|2, L. Barcella1|2 | 1Hemostasis & Thrombosis Center, Department of Transfusion Medicine, Papa Giovanni XXIII Hospital, Bergamo, Italy; 2ERN EuroBloodNet; 3Hematology Unit, Department of Translational and Precision Medicine, Sapienza University of Roma, Roma, Italy; 4Pulmonary Unit, Hospital of Siena, University of Siena, Siena, Italy; 5Hemostasis and Thrombosis Unit, Hospital of Siena, University of Siena, Siena, Italy; 6Haematology Unit, Ordine Mauriziano Hospital, Torino, Italy; 7Department of Medicine, University of Padua, Padova, Italy; 8Department of Medicine, Maggiore Hospital, Bologna, Italy; 9Department of Medicine, Sondalo Hospital, Sondalo, Italy; 10Angiology Unit, Sant'Eugenio Hospital, Roma, Italy; 11Arianna Anticoagulazione Foundation, Bologna, Italy; 12Department of Critical Care Medicine, Thrombosis Centre, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy
143PDF: 17 -
PO37 | Single centre experience on anticoagulation in carriers of non-mild inherited thrombophilia: direct oral anticoagulants (DOAC) efficacy and safety M. D’uva1,2, G. La Barba1, G. Montanaro1, M. Di Ianni1,2, P. Ranalli1,2 | 1Hematology Unit, S. Spirito Hospital, Pescara; 2Department of Medicine and Aging Sciences, D’Annunzio University, Chieti, Italy
658PDF: 25 -
PO36 | Venous stenting for symptomatic iliac thrombosis: five-years experience of single center I. Nichele1, G. Marchesini1, L. Boi2, G. Carli1, A. Tosetto1 | 1Hemophilia and Thrombosis Center, Hematology Department, S. Bortolo Hospital, Vicenza; 2Radiology Department, Ospedale Ca’ Foncello, Treviso, Italy
637PDF: 30 -
PO11 | THROMBOEMBOLIC EVENTS DURING PERIOPERATIVE THERAPY FOR RESECTABLE AND BORDERLINE RESECTABLE PANCREATIC CANCER IN THE PREOPANC-2 TRIAL R.A.L. Willems1|5, A.E. Van Diepen1|2|6, EN. Dekker7, Q.P. Janssen7, J.L. Van Dam7, N. Michiels8, C.W.F. Van Eijck9, K.E.P.E. Hermans1|2, B.A. Bonsing8, K.P. Bosscha10, S.A.W. Bouwense11|12, O. R. Busch13|14, H. Ten Cate4|5|15|16, P.P.L.O. Coene17, C.H.J. Van Eijck7, N. Van Es18|19, E. Van Der Harst17, I.H.J.T. De Hingh20, T.M. Karsten21, G. Kazemier13|14, M.B. Van Der Kolk22, B. De Laat3|5, M.S.L. Liem22, J.S.D. Mieog8, V.B. Nieuwenhuijs24, G.A. Patijn24, M. Roest3, H.C. Van Santvoort25, L. Valkenburg-Van Iersel1|2, R. F. De Wilde7, F. Wit26, B.M. Zonderhuis13|14, M.G. Besselink13|14, M.Y.V. Homs6, G. Van Tienhoven14|27, J. W. Wilmink14|28, B. Groot Koerkamp7, J. De Vos-Geelen1|2 | 1Maastricht University Medical Center, Department of Internal Medicine, Division of Medical Oncology; 2GROW – Research Institute for Oncology & Reproduction, Maastricht University, Maastricht; 3Synapse Research Institute, Department of Functional Coagulation, Maastricht; 4Maastricht University Medical Center, Thrombosis Expert Center Maastricht, Maastricht; 5Maastricht University Medical Center, Cardiovascular Research Institute Maastricht (CARIM), School for Cardiovascular Diseases, Maastricht; 6Erasmus MC Cancer Institute, Department of Medical Oncology, Rotterdam; 7Erasmus MC Cancer Institute Rotterdam, University Medical Center Rotterdam, Department of Surgery; 8Leiden University Medical Center, Department of Surgery, Leiden; 9Solid Tumour Immunology Research Rotterdam (STIRR), Department of Pulmonary Medicine, Erasmus University Medical Centre, Rotterdam; 10Jeroen Bosch Hospital, Department of Surgery, Den Bosch; 11Maastricht University Medical Center, Department of Surgery, Maastricht; 12Maastricht University Medical Center, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht; 13Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam; 14Cancer Center Amsterdam; 15Maastricht University Medical Center, Department of Internal Medicine, Division Vascular Medicine, Maastricht; 16Maastricht University, Department of Biochemistry, Laboratory for Clinical Thrombosis and Hemostasis, Maastricht; 17Maasstad Hospital, Department of Surgery, Rotterdam; 18Amsterdam UMC, location University of Amsterdam, Department of Vascular Medicine, Amsterdam; 19Amsterdam UMC, location University of Amsterdam, Amsterdam Cardiovascular Sciences, Pulmonary Hypertension & Thrombosis, Amsterdam; 20Catharina Hospital, Department of Surgery, Eindhoven; 21OLVG, Department of Surgery, Amsterdam; 22Radboud University Medical Center, Department of Surgery, Nijmegen; 23Medisch Spectrum Twente, Department of Surgery, Enschede; 24Isala Oncology Center, Department of Surgery, Zwolle; 25Regional Academic Cancer Center Utrecht, St. Antonius Hospital and University Medical Center Utrecht, Department of Surgery, Utrecht; 26Frisius MC, location Leeuwarden, Department of Surgery, Leeuwarden; 27Amsterdam UMC, location University of Amsterdam, Department of Radiation Oncology, Amsterdam; 28Amsterdam UMC, location University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands
447PDF: 96 -
OC03 | THROMBOEMBOLIC PREVALENCE IN MULTIPLE MYELOMA BEFORE AND AFTER THE INTRODUCTION OF DIRECT ORAL ANTICOAGULANTS: A LONGITUDINAL COHORT STUDY A. Ramírez1, A. Orozco2, A. Sánchez3, F. Villalpa1, S. Burgos2, G. Cesarman3, G. Rodríguez1, D. Vieyra2, J. Álvarez4, G.M. Flores3, S. González1, D. Martínez2, B. Cabello3, R. Espinoza3, O. Fernández3 | 1Myeloma-clinic Hematology service, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, México City, México; 2Myeloma-clinic Hematology service, Instituto Nacional de Nutrición Salvador Zubirán, México City, México; 3Myeloma-clinic Hematology service, Instituto Nacional de Cancerologçia, México City, Mexico; 4Centro Médico Nacional 20 de Noviembre, México City, Mexico
508PDF: 110 -
PO113 | A STRANGE CASE OF RECURRENT ISOLATED DIGITAL ARTERIAL THROMBOSIS M.M. Poggi, D. Bruni | SOC Medicina 1, Nuovo Ospedale Prato, Prato, Italy
35PDF: 19 -
PO29 | CANADIAN INSIGHTS INTO THE MANAGEMENT OF BREAKTHROUGH THROMBOSIS S. Ramdani1, C. Séguin2 | 1Division of Hematology, Post-Graduate Medical Education Program, McGill University, Montreal; 2Division of Hematology, Department of Medicine, McGill University Health Center, Montreal, Canada
496PDF: 99 -
PO067 | LONG‑TERM SAFETY AND EFFECTIVENESS OF VITAMIN K ANTAGONISTS IN PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES: A RETROSPECTIVE COHORT ANALYSIS G. Sottilotta1, G. Praticò1, D. Megalizzi1, F. Luise2 | 1UOSD Centro per le Microcitemie - Servizio Emostasi e Trombosi; 2Laboratorio Analisi, Grande Ospedale Metropolitano di Reggio Calabria, Italy
36PDF: 17 -
CO048 | PREDICTORS OF FIRST THROMBOTIC EVENTS AFTER MECHANICAL VALVE REPLACEMENT FOR RHEUMATIC HEART DISEASE: A RETROSPECTIVE COHORT STUDY FROM SALAM CENTER FOR CARDIAC SURGERY (SUDAN) N. Erba1|3, S. Abdelwahab Abdallah1, D. Poli3, M. Langer2, G. Portella2, E. Giovanella1, F. Masini1, P. Malerba2 | 1The Salam Centre for Cardiac Surgery, Emergency NGO, Khartoum, Sudan; 2Emergency NGO Milano, Italy; 3Federazione dei Centri per la diagnosi della trombosi e la Sorveglianza delle terapie Anti trombotiche, Italy
60PDF: 16 -
PO31 | Comparative analysis of anticoagulant therapy in patients over 90 years old: vitamin K antagonists versus direct oral anticoagulants G. Sottilotta1, P. Arrigo2, S. Cuzzocrea1, D. Megalizzi1, F. Luise3 | 1UOSD Microcitemie, Emostasi e Trombosi, Grande Ospedale Metropolitano di Reggio Calabria; 2Associazione Italiana Pazienti Anticoagulati, Sezione di Reggio Calabria; 3Laboratorio Analisi. Grande Ospedale Metropolitano di Reggio Calabria, Italy
606PDF: 19 -
PO72 | CATHETER-RELATED THROMBOSIS VS. FIBROBLASTIC SLEEVE. INCIDENCE AND IMPACT IN ONCOLOGICAL AND HEMATOLOGICAL PATIENTS WITH PERIPHERALLY INSERTED CENTRAL CATHETER M. Nunziata1, S. Mangiacapra1, F.P. Damiano1, N. Iuliano1, V. Iorio1, R. Natale2, L. Santarpia2, M. Amitrano1 | 1Internal Medicine, A.O.R.N. San Giuseppe Moscati, Avellino, Italy; 2Internal Medicine, Department of Clinical Medicine and Surgery, Federico II University Hospital, Naples, Italy
530PDF: 122 -
Availability of direct oral anticoagulants testing among Italian anticoagulation clinics: a rapid evolution of clinical practice On behalf of the Italian Federation of Centers for the Diagnosis of Thrombotic Disorders and the Surveillance of the Antithrombotic Therapies
879PDF: 103 -
PO76 | Thrombosis associated with midline in autoimmune patient: a case report on the use of apixaban in a real-world setting M.V. Cherchi, M. Anedda, S. Che, M. Vacca, M. Caboni, M. Mantega | Department of Internal Medicine, ASL Sulcis, Italy
608PDF: 34 -
PO38 | Rates of hemorrhagic events and hemodialysis circuit thrombosis in patients with end-stage renal disease on hemodialytic treatment receiving a factor-XI inhibitor: a systematic review and meta-analysis D. Santagata, G. Barbui, M.P. Donadini, A. Squizzato | Department of Medicine and Surgery, Research Center on Thromboembolic Disorders and Antithrombotic Therapies, University of Insubria, Varese and Como, Italy
625PDF: 31 -
CO04 | Direct oral anticoagulants in antiphospholipid syndrome: a single center real-life experience A. Hoxha1, E. Campello1, F. Ahmad2, L. Spiezia1, P. Scarinzi1, G. Gobbo1, S. Gavasso1, F. Sartorello1, C. Simion1, E. Zanon1, P. Simioni1 | 1Internal Medicine Unit, Thrombotic and Haemorrhagic Centre, Department of Medicine - DIMED; 2Department of Statistical Sciences) University of Padova, Italy
769PDF: 25 -
CO006 | PREVALENCE OF GASTROINTESTINAL BLEEDING IN GLANZMANN THROMBASTHENIA PATIENTS: RESULTS OF A WORLDWIDE SURVEY E. Falcinelli1, L. Bury1, S. Morais2, M. de Oliveira2, M. Kannan3, M. Faranoush4, D. Desprez5, V. Jean-Baptiste6, C. Santoro7, C. Falaise8, P. Saultier8, M. Fiore9, C. Albayrak10, A. Sánchez11, J.M. Bastida12, A. Artoni13, G. Castaman14, K. Gomez15, R. Schutgens16, L. Spiezia17, M. Sridharan18, N. Butta19, P. Buur van Kooten Niekerk20, E. Leinøe21, B. Guillet22, C. Panagiotis23, S. Crivelli24, E. De Candia25, M. Lewandowska26, P. De Bonis27, G. Kenet28, F. Heubel-Moenen29, J. Payne30, L. Banov31, L. Puccetti32, M. Olivieri33, M. Chitlur34, M. Lambert35, A. Pecci36, D. Martínez-Carballeira37, E. Zetterberg38, J. Curnow39, M. Napolitano40, A. Morotti41, R.C. Santoro42, R. Johann43, S. Saulyte Trakymiene44, A. Falanga45, C. Casas46, E. Zanon47, J. Moppet48, N.M. Popa-Fotea49, P. Gresele1 | 1Department of Medicine and Surgery, Section of Internal and Cardiovascular Medicine, University of Perugia, Italy; 2Centro Hospitalar Universitário de Santo António, Portugal; 3Blood and Vascular Biology Research Lab, Department of Biotechnology, Central University of Tamil Nadu, India; 4Iranian Hemophilia and Thrombophilia Association, MAHTA, Iran; 5CRC MHC Hopital Universaitire de Strasbourg, France; 6CHRU de Tours, University Hospital of Tours, France; 7UOC Ematologia, Azienda Ospedaliero Universitaria Policlinico Umberto I, Roma, Italy; 8AP-HM Timone, Marseille, France; 9CHU Bordeaux, France; 10Mayıs University Medical Faculty Pediatric Hematology and Oncology Dept, Türkiye; 11Hospital Universitario Morales Meseguer – Centro Regional de Hemodonación, Murcia, Spain; 12Complejo Asistencial Universitario De Salamanca, Spain; 13Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy; 14Azienda Ospedaliera Universitaria Careggi Florence, Italy; 15Royal Free Hospital, London, UK; 16Center for Benign Haematology, Thrombosis and Haemostasis, Van Creveldkliniek, UMC Utrecht, The Netherlands; 17University of Padova, Italy; 18Mayo Clinic, Rochester, USA; 19Hospital Universitario La Paz-IdiPAZ, Madrid, Spain; 20Aarhus University Hospital, Denmark; 21Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; 22University Hospital of Rennes, France; 23Blood unit and National Reference Center for Congenital Bleeding Disorders, ''Laiko'' General Hospital, Greece; 24Ospedale L. Sacco e Polo Universitario, Milano, Italy; 25Università Cattolica del Sacro Cuore-Roma, Fondazione Policlinico Universitario A. Gemelli IRCCS, Italy; 26Indiana Hemophilia and Thrombosis Center Innovative Hematology, USA; 27IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy; 28Sheba Medical Center, Israel; 29Department of Hematology Internal Medicine, Maastricht University Medical Center and Hemophilia Treatment Center Nijmegen Eindhoven Maastricht and CARIM, Maastricht University, Maastricht, Netherlands; 30Sheffield Children’s NHS foundation Trust, UK; 31Hemostasis and Thrombosis Unit, Gaslini Children’s Hospital, Italy; 32University Teaching Hospital of Siena, Italy; 33Pediatric Thrombosis and Hemostasis Unit, Dr. von Hauner Childreńs Hospital, LMU Munich, Munich, Germany; 34Children's Hospital of Michigan, USA; 35Children’s Hospital of Philadelphia, USA; 36IRCCS Policlinico San Matteo Foundation and University of Pavia, Italy; 37Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Spain; 38Department of Hematology, Coagulation Unit, Skane University hospital, Sweden; 39Westmead Hospital, Sydney, Australia; 40PROMISE Department, University of Palermo, Italy; 41AOU San Luigi Gonzaga Hospital, University of Turin, Italy; 42Hemostasis and Thrombosis, Az. Osp. Univ. Dulbecco, Catanzaro, Italy; 43Hospital Center of Le Mans, France; 44Vilnius University Hospital Santaros Klinikos, Lithuania; 45ASST Papa Giovanni XXIII, Bergamo, Italy; 46Hospital San José, Bogotà, Colombia; 47Haemophilia Center-General Medicine, Padova University Hospital, Padova, Italy; 48University Hospitals Bristol NHS Foundation Trust, UK; 49University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania
152PDF: 14 -
PO63 | Atypical venous thrombosis in young patient with systemic lupus erythematosus and high-risk APL profile: provoked or not? E. Marrone, A. Parisi, G. Di Monda, F. Gallucci, D. Morelli, C. Romano, U. Malgeri, D. D’Auria, P. Morella | Internal Medicine Unit 3, Cardarelli Hospital, Naples, Italy
617PDF: 26 -
PO155 | MANAGEMENT OF ANTICOAGULANT THERAPY IN IMMUNOTHROMBOSIS SECONDARY TO TOXOPLASMA INFECTION A. Grembiale1, A. Sabena1, G. Dettori1, C. Grendene1, S. Grazioli1, S. Venturini2 | 1SOC Medicina Interna 2 - Azienda Sanitaria Friuli Occidentale - Pordenone, Italy; 2SSD Malattie Infettive - Azienda Sanitaria Friuli Occidentale - Pordenone, Italy
55PDF: 21 -
PO49 | PROPHYLACTIC ANTICOAGULATION DECISIONS IN HIGH-RISK PATIENTS RECEIVING CANCER-DIRECTED THERAPY: ANALYSIS OF THE VERMONT METHOD J. Barker1, K. Libby1, C. Holmes2, K. Martin2 | 1University of Vermont Health System; 2Department of Medicine, University of Vermont, Burlington, VT, USA
473PDF: 107 -
The use of creatine and the development of deep vein thrombosis. A scoping review
9070PDF: 829Supplementary: 213 -
Still unmet problems with low molecular weight heparin prophylaxis of venous thromboembolism. An Italian survey
1459PDF: 315HTML: 207Supplementary: 103 -
CO-37 | STEW-EFA STUDY: MULTICENTER EVALUATION OF ONE-STAGE AND CHROMOGENIC ASSAYS FOR EFANESOCTOCOG ALFA MEASUREMENT ON STAGO AND WERFEN PLATFORMS A.C. Molinari1, M. Marchetti2, A. Catalano3, L. Contino4, R. De Cristofaro5, A.B. Federici6, T. Martini7, I. Quaglia8, R. Rossi9, R. Santoro10, A. Tripodi11, A. Valpreda12 | 1Regional Reference Centre for Hemorrhagic Diseases, Department of Hemato-Oncology, IRCCS Istituto Giannina Gaslini, Genova, Italy; 2Department of Immunohematology and Transfusion Medicine, ASST Papa Giovanni XXIII, Bergamo, Italy; 3Società per la Promozione dell'educazione Medica (S.P.E.Me), Italy; 4Hemostasis and Thrombosis Unit, AOU SS Antonio e Biagio e C Arrigo, Alessandria, Italy; 5Dipartimento di Medicina e Chirurgia Traslazionale, Facoltà di Medicina e Chirurgia "Agostino Gemelli," Università Cattolica S. Cuore, Roma, Italy - Servizio Malattie Emorragiche e Trombotiche, Fondazione Policlinico Universitario "A. Gemelli" Istituto di Ricerca e Cura a Carattere Scientifico, Roma, Italy; 6School of Medicine and Surgery, University of Milan-Bicocca, Milano, Italy; 7Hemophilia Centre, Immune-Hematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza", Torino, Italy; 8Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital Rozzano, Milan, Italy; 9Laboratory of Clinical Chemistry and Hematology, University Hospital of Parma, Italy; 10Hemophilia, Hemostasis, and Thrombosis Unit, Azienda Ospedaliero Universitaria Dulbecco, Catanzaro, Italy; 11IRCCS Ca' Granda Maggiore Hospital Foundation and Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milano, Italy; 12Central Laboratory Baldi and Riberi, AOU Città della Salute e della Scienza, Turin, Italy, reference laboratory of the Regional Center for Hemostasis and Thrombosis.
44PDF: 18 -
PO81 | Direct oral anticoagulants in atypical site vein thrombosis: a single centre experience focused on cancer patients U. Mazzarelli1, A. Guida1, L. Agrelli1, M. Amato1, R. Guarrasi2, L. Santaniello2, C. Cardamone1, P. Vitale1, M. Triggiani1 | 1Centro per le Malattie Emorragiche Congenite e Malattie Trombotiche UOC Clinica Immunologica e Reumatologica AOU S. Giovanni di Dio e Ruggi d’Aragona, Salerno; 2UOC Clinica Oncologica AOU S. Giovanni di Dio e Ruggi d’Aragona, Salerno, Italy
644PDF: 29 -
PO91 | Disseminated intravascular coagulation with deep vein thrombosis in a frail patient: an extreme manifestation triggered by sepsis during SGLT2i therapy M. Vacca1, M.V. Cherchi1, S. Che1, G.A.M.L. Costanzo2, D. Firinu2, M. Mantega1, S. Del Giacco2 | 1Ospedale Sirai, ASL Sulcis, 2Università degli Studi di Cagliari, Italy
809PDF: 22 -
PO130 | HEMORRHAGIC AND THROMBOTIC COMPLICATIONS DURING DOACS TREATMENT: THE IMPORTANCE OF A REGULAR AND PROLONGED FOLLOW-UP D. Barcellona1|2, A. Mameli2, S. Cornacchini2, P. Schirru2, L. Fenu2, V. Casu2, F. Marongiu1|2 | 1University of Cagliari, Italy; 2Haemostasis and Thrombosis Unit, Azienda Ospedaliero-Universitaria di Cagliari, Italy
46PDF: 10 -
CO065 | THROMBOTIC RISK IS NOT UNIFORM ACROSS APHERESIS SETTINGS: INSIGHTS FROM CAR-T LYMPHOCYTAPHERESIS AND AUTOLOGOUS STEM CELL COLLECTION I. Pansini1|2, G. Brizzi2, E. Galli1, A. Corrente2, P. Rea2, N. Piccirillo1|2, M. Viscovo1|2, S. Hohaus1|2, P. Chiusolo1|2, F. Sorà1|2, S. Sica1|2 | 1Fondazione Policlinico Universitario A. Gemelli, Italy; 2Università Cattolica del Sacro Cuore, Italy
57PDF: 14 -
PO35 | Cerebral veins thrombosis in patients with and without myeloproliferative neoplasm: a real life retrospective monocentric study I. Bertozzi, M.T. Sartori, M. Zerbinati, G. Libralon, A. Galbiati, P. Simioni | First Medical Clinic, Department of Medicine - DIMED, Università degli Studi di Padova, Italy
609PDF: 30 -
PO80 | Heparin-induced thrombocytopenia: a monocentric experience with danaparoid L. D’Innocenzo, S. Sorrentino, M. De Siati, A. Ferretti, E. De Candia | Unit of Haemostasis and Thrombosis Diseases, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Roma, Italy
708PDF: 17 -
PO21 | PSYCHOLOGICAL IMPACT OF CANCER-ASSOCIATED THROMBOSIS: DUAL BURDEN AND IMPLICATIONS FOR QUALITY OF LIFE AND INTEGRATED PATIENT-CENTERED CARE G. Gerotziafas1|4, Y. Mitrou5, M. Marchetti6, P. Las Casa1, A. Tafur7, V. Bitsadze3, J. Khizroeva3, D. Taizhanova8, D. Antic9, C. Frére10, A. Makatsariya3, L. Garderet1|11, A. Escargueil1, C. Ay12, N. Lomatkin13, Z. Tazi-Mezalek14, M. Sassi15, M. Catalano4|16, J. Gligorov1|17, J. Caprini18, P. Van Dreden1|19, J. Fareed2, A. Falanga6 | 1Sorbonne University, INSERM UMR_S_938, CRSA, Research Department "Cancer, Vessels, Biology and Therapeutics" (CaVITE), Research Group "Cancer-Angiogenesis-Thrombosis and Haemostasis," Thrombosis Center, University Institute of Cancerology (UIC), Saint Antoine University Hospital Assistance Publique Hôpitaux de Paris (AP-HP)Paris France; 2Center of Translational Research and Education, Department of Pathology and Laboratory Medicine, Loyola University Stritch School of Medicine, Maywood, Chicago, USA; 3Thrombosis Center, Department of Obstetrics, Gynecology and Perinatal Medicine, The I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; 4VAS-European Independent Foundation in Angiology/Vascular Medicine Milan Italy; 5Department of Phylosophy, National and Kapodistrian University of Athens, Greece; 6Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy. School of Medicine and Surgery, University of Milan Bicocca, Milan, Italy; 7Vascular Medicine, Endeavor Health, Evanston, IL, USA; Pritzker School of Medicine, University of Chicago, Chicago, IL 60637, USA; 8Department of Internal Diseases, Karaganda Medical University Non-Commercial Joint Stock Company, Karaganda, Kazakhstan; 9Clinic for Hematology, University Clinical Center of Serbia, Faculty of Medicine University of Belgrade Belgrade Serbia; 10Department of Hematology, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, INSERM UMRS-1166 Institute of Cardiometabolism and Nutrition, Paris, France; 11Clinical Haematology Department, Sorbonne Université, Pitié-Salpêtrière Hospital, APHP, Paris; 12Department of Internal Medicine I, Clinical Division of Haematology and Haemostaseology, Medical University of Vienna, Vienna, Austria; 13Cardiology Division, Central Clinical Hospital of Presidential Administration, Moscow, Russia; 14Department of Internal Medicine, Hématologie Clinique, Centre Hospitalo-Universitaire Ibn Sina, Université Mohammed V de Rabat, Rabat, Morocco; 15Hematology Laboratory of Maternity and Neonatal Center of Monastir, Faculty of Pharmacy of Monastir, Monastir, Tunisia; 16Inter-University Research Center on Vascular Diseases, University of Milan-L Sacco Hospital, Milan, Italy; 17Medical Oncology Department, Tenon Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne University, Paris, France; 18Vascular Surgery, Pritzker School of Medicine at the University of Chicago, Chicago, USA; 19Clinical Research, Diagnostica Stago, Gennevilliers, France
462PDF: 96 -
CO-22 | CLINICAL FEATURES IN PATIENTS WITH NON-SEVERE HEMOPHILIA A: THE DISCOVERY SCORE PROPOSAL FOR PROPHYLAXIS PRESCRIPTION M.N.D. Di Minno1, E. Baldacci2, C. Biasoli3, A. Borchiellini4, F. Daniele5, P. Di Gregorio6, C. Gorio7, G. Malcangi8, E. Marchesini9, I. Ricca10, R. Santoro11, S. Siragusa12, M.R. Villa13, E. Zanon14, A. Tagliaferri15, A. Coppola15 | 1Hub Centre for Thrombotic and Hemorrhagic Disorders, Federico II University Hospital, Napoli, Italy; 2Haematology, University Hospital Policlinico Umberto I, Roma, Italy; 3Interdepartmental Simple Structure for the Management of Hemorrhagic and Thromboembolic Diseases, M. Bufalini Hospital, Cesena, Italy; 4Regional Centre for Hemorrhagic and Thrombotic Diseases, AOU Città della Salute e della Scienza, Torino, Italy; 5Haemostasis and Thrombosis Service, Ospedale Civile dell'Annunziata, Cosenza, Italy; 6Transfusion Medicine Department, "SS. Annunziata" Hospital, Chieti, Italy; 7Pediatric Onco-Hematology Unit, Children's Hospital, ASST-Spedali Civili, Brescia, Italy; 8Haemophilia and Thrombosis Center, University Hospital Policlinico-Giovanni XXIII, Bari, Italy; 9Hemophilia Centre, SC Vascular and Emergency Department, University of Perugia, Italy; 10Centro Emofilia, Città della Salute e della Scienza, Torino, Italy; 11Hemostasis and Thrombosis Unit, Azienda Ospedaliero Universitaria Dulbecco, Catanzaro, Italy; 12Centro di Riferimento Regionale per le Emocoagulopatie Congenite, Palermo, Italy; 13Hematology Unit, Ospedale Santa Maria di Loreto, Napoli, Italy; 14Hemophilia and Thrombosis Center, University Hospital of Padua, Italy; 15Hemophilia and Thrombosis Center, Azienda Ospedaliera di Parma, Italy
74PDF: 18 -
PO066 | ONE IN TWO MILLION: A 'DOUBLE-HIT' CASE OF INFRARENAL VENA CAVA AGENESIS AND TRIPLE-POSITIVE ANTIPHOSPHOLIPID SYNDROME N. Portesi, S. Pontoglio, G. Martini | ASST Spedali Civili di Brescia, Italy
41PDF: 16 -
PO01 | MELANOMA-DERIVED EXTRACELLULAR VESICLES DRIVE VON WILLEBRAND FACTOR–DEPENDENT THROMBOSIS AND METASTASIS Y. Wang1|2, X. Liu1, T. Downar3, A. Topuz4, A. Bauer1, J. Kött1|5, K. Nekipelov6, S. Brenna7, G. Bendas6, B. Puig7, S. Schneider1, D. Fedosov4, C. Gorzelanny1 | 1Department of Dermatology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 2Mildred Scheel Cancer Career Center HaTriCS4, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 3Experimental Dermatology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; 4Institute for Advanced Simulation (IAS-2), Forschungszentrum Jülich, Jülich, Germany; 5Fleur Hiege Center for Skin Cancer Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 6Pharmaceutical Institute, University of Bonn, Bonn, Germany; 7Neurology Department, Experimental Research in Stroke and Inflammation (ERSI), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
504PDF: 112 -
CO06 | Recurrences of catheter associated upper extremity deep vein thrombosis in cancer: a two year prospective study with enoxaparin M. Sartori, A. Trentini, S. Cavara, L. Borgese, M. Soldati, B. Cosmi | Angiology and Blood Coagulation Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy
686PDF: 31 -
PO65 | OVARIC CANCER PRESENTING WITH COLD-AGGLUTININ MEDIATED HEMOLYTIC ANEMIA, PULMONARY THROMBOEMBOLISM AND DEEP VEIN THROMBOSIS R. Cannas | Hemostasis and thrombosis Center, Ospedale Santissima Trinità, ASL Cagliari, Italy
546PDF: 119 -
CO007 | TPO-RECEPTOR AGONISTS AS AN INDEPENDENT RISK FACTOR FOR VENOUS THROMBOTIC EVENT IN IMMUNE THROMBOCYTOPENIA PATIENTS WITH PERSISTENT ANTIPHOSPHOLIPID ANTIBODIES POSITIVITY M. Biglietto, B. Mandelli, S. Sorella, S. Ligia, C. Andriola, R. Mormile, E. Baldacci, A. Chistolini, S. Truglia, C. Santoro | Sapienza, University of Rome, Italy
144PDF: 14 -
PO26 | OUTCOMES OF DIRECT ORAL ANTICOAGULANTS IN UNUSUAL-SITE THROMBOSIS: IMPACT OF ACTIVE CANCER S. Guglielmo1, M. Lovisotto1, L. Scarano1, E. De Bon2, S. Barbar2 | 1Internal Medicine, Department of Medicine, Azienda Ulss 6 Euganea, Cittadella (PD), Italy; 2Thrombotic and Hemorrhagic Disorders Unit, Department of Medicine, Azienda Ulss 6 Euganea, Cittadella (PD), Italy
531PDF: 111 -
PO28 | Long term effectiveness and safety of venous thromboembolism with fondaparinux: data from the start registry I.M. Palumbo1, E. Valeriani1,2, A. Pannunzio1, S. Marucci3, D. Menichelli1, D. Pastori3,4, P. Pignatelli3 | 1Department of General Surgery and Surgical Specialty, Sapienza University of Roma; 2Department of Infectious Disease, Azienda Ospedaliero-Universitaria Policlinico Umberto I, Roma; 3Department of Clinical Internal, Anaesthesiologic and Cardiovascular Sciences, Sapienza University of Roma, Roma; 4IRCCS NeuRomad, Pozzilli, Italy
647PDF: 16 -
PO108 | DIRECT ORAL ANTICOAGULANTS IN PATIENTS WITH VENOUS THROMBOEMBOLISM RECEIVING LONG-TERM IMMUNOSUPPRESSIVE THERAPY AFTER LIVER AND KIDNEY TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE U. Mazzarelli1, L. Agrelli1, A. Cirillo1, C. Crescenzo2, M. Triggiani1, A. Guida3 | 1Dipartimento di Medicina Interna, Università degli studi di Salerno, Italy; 2UOC Nefrologia e Trapianti di rene; 3Centro per le malattie emorragiche congenite e malattie trombotiche, AOU San Giovanni di Dio e Ruggi d'Aragona Salerno, Italy
54PDF: 15 -
PO39 | RISK OF VENOUS THROMBOEMBOLISM ASSOCIATED WITH PERIPHERALLY INSERTED CENTRAL CATHETERS IN CANCER PATIENTS RECEIVING CHEMOTHERAPY: A REAL-WORLD SINGLE-CENTRE EXPERIENCE S. Gilani, H. Rubbani, A. Mackie | Cancer Centre, University Hospitals of North Midlands, Staffordshire, UK
511PDF: 112 -
CO05 | Long-term management of upper extremity catheter-related thrombosis in female patients with cancer: a retrospective cohort study Chiara Cavallaro1,2, Paolo Santini1,2, Laura Leoni3, Carolina Mosoni1,2, Silvia D’Ambrosio1,2, Francesco Mancinetti1,2, Nicola Coletta1,2, Michela Iorio1,2, Angelo Porfidia1,2, Alessandro D’Errico1,2, Rosa Talerico1,2, Roberto Pola1,2 | 1Department of Aging, Orthopedic, and Rheumatologic Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome; 2Università Cattolica del Sacro Cuore, Rome; 3Vita-Salute University, San Raffaele Hospital IRCCS, Milan, Italy
681PDF: 31 -
Inherited platelet function disorders: a comprehensive narrative review focusing on diagnostic and management aspects
88PDF: 43SUPPLEMENTARY MATERIAL: 15 -
PO50 | SUB-ANALYSIS OF INTERIM RESULTS FROM A PHASE 2 STUDY INVESTIGATING REGN9933A2 AND REGN7508CAT FOR THE PREVENTION OF CONTACT-MEDIATED VENOUS THROMBOEMBOLISM IN PATIENTS WITH ACTIVE CANCER UNDERGOING PERIPHERALLY INSERTED CENTRAL CATHETER PLACEMENT (ROXI-CATH) J. Zwicker1,2, A.P. Kithcart3, J. Kaplan3, Y-C. Cheng3, J.G. Raya3, J. Xiao3, S. Li3, K. Musgrave4, D.E. Gutstein3, G. Piazza5 | 1Memorial Sloan Kettering Cancer Center, New York, NY, USA; 2Weill Cornell Medical Center, New York, NY, USA; 3Regeneron Pharmaceuticals, Inc. , Tarrytown, NY, USA; 4Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; 5Brigham and Women’s Hospital, Boston, MA, USA
515PDF: 130 -
PO003 | CATHETER-RELATED THROMBOSIS IN CANCER PATIENTS: A RETROSPECTIVE REAL-WORLD STUDY G. Autiero1|3, S.A. Malerba1|2|4, F. Busato1|2, D. Tolomio1|2, M. Dalla Vestra1|2, F. Presotto1|2 | 1U.O. Medicina Generale, Osp. Dell'Angelo, Venezia-Mestre, Italy; 2U.O. Angiologia, Osp. Dell'Angelo, Venezia-Mestre, Italy; 3Dip. Medicina Interna, Università degli Studi di Padova, Italy; 4U.O.C. Medicina Generale ad indirizzo trombotico ed emorragico, Università degli studi di Padova, Italy
34PDF: 15 -
PO60 | VEXAS SYNDROME AS A NEW SEVERE THROMBOPHILIC CLONAL CONDITION: A SINGLE CENTRE EXPERIENCE C. Ambaglio1, E. Galimberti1, F. Schieppati1, M. Frigeni2, M. Marchetti1, L. Barcella1, A. Falanga 1|3 | 1Immunohematology and Transfusion Medicine Unit, ASST Papa Giovanni XXIII, Bergamo; 2Hematology and Bone Marrow Transplant Unit, ASST Papa Giovanni XXIII, Bergamo; 3School of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy
510PDF: 112 -
PO12 | IMPACT OF INHERITED THROMBOPHILIA ON CANCER-ASSOCIATED THROMBOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS E. Campello1, G. Furlan1, A. Boccatonda2, A. Napolitano1, C. Simion1, P. Simioni1 | 1Internal Medicine 1 and Thrombotic and Hemorrhagic Diseases Unit, Department of Medicine, University of Padova, Italy; 2Diagnostic and Therapeutic Interventional Ultrasound Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola-Malpighi, Bologna, Italy
488PDF: 113 -
PO012 | RECURRENT CENTRAL RETINAL VEIN THROMBOSIS IN A PATIENT WITH MILD HEMOPHILIA A AND HETEROZYGOSITY FOR THE PROTHROMBIN G20210A VARIANT I. Zatta1, E. Pacquola1, L. Di Daniel2, C. Simion3, E. Zanon3, P. Simioni3, S. Villalta2, L. Abbruzzese1 | 1Medicina Trasfusionale Osp. Ca’ Foncello, Treviso, Italy; 2Medicina Generale Osp. S. Giacomo, Castelfranco V.to, Italy; 3Clinica Medica 1° Azienda-Ospedale Università, Padova, Italy
60PDF: 17
